Literature DB >> 8018528

Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.

J M Klaase1, B B Kroon, J H Beijnen, G W van Slooten, J A van Dongen.   

Abstract

In 14 consecutive patients with recurrent melanoma of the lower limb a total of 35 biopsies were taken at the end of perfusion treatment to assess melphalan tissue concentrations in tumour, skin/subcutis and muscle tissue. In tumour tissue (n = 12) the mean melphalan concentration was 6.8 micrograms g-1, which was significantly higher than that of healthy skin/subcutis (3.2 micrograms g-1; n = 10), but equal to that of muscle tissue (6.5 micrograms g-1; n = 13). The correlation between melphalan concentration in the tissues and the concentration in the perfusate was studied. The latter was assessed in the form of melphalan peak concentration and the area under the curve (AUC0-->60) of the melphalan concentration-time curve. Tumour concentration proved to be correlated linearly with AUC0-->60 (R = 0.6, P = 0.002) and muscle concentration with melphalan peak concentration (R = 0.8, P = 0.04). There was no relation between skin/subcutis concentrations and the perfusate parameters. Further research is warranted to study the relationship between melphalan tissue concentration, tumour response and regional toxicity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018528      PMCID: PMC2033317          DOI: 10.1038/bjc.1994.266

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  7 in total

1.  Action of p-[di(2-chloroethyl)]-amino-l-phenylalanine on Harding-Passey mouse melanoma.

Authors:  J M LUCK
Journal:  Science       Date:  1956-06-01       Impact factor: 47.728

2.  Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics.

Authors:  C Benckhuijsen; B B Kroon; A N van Geel; J Wieberdink
Journal:  Eur J Surg Oncol       Date:  1988-04       Impact factor: 4.424

3.  Regional isolation perfusion in melanoma of the limbs; accomplishments, unsolved problems, future.

Authors:  B B Kroon
Journal:  Eur J Surg Oncol       Date:  1988-04       Impact factor: 4.424

4.  A comparison of melphalan transport in human breast cancer cells and lymphocytes in vitro.

Authors:  A Begleiter; E K Froese; G J Goldenberg
Journal:  Cancer Lett       Date:  1980-09       Impact factor: 8.679

5.  Mechanism of melphalan resistance developed in vitro in human melanoma cells.

Authors:  P G Parsons; F B Carter; L Morrison
Journal:  Cancer Res       Date:  1981-04       Impact factor: 12.701

6.  Hydrolysis and protein binding of melphalan.

Authors:  S Y Chang; D S Alberts; D Farquhar; L R Melnick; P D Walson; S E Salmon
Journal:  J Pharm Sci       Date:  1978-05       Impact factor: 3.534

7.  Pharmacokinetics of melphalan in isolated perfusion of the limbs.

Authors:  C Benckhuijsen; F J Varossieau; A A Hart; J Wieberdink; J Noordhoek
Journal:  J Pharmacol Exp Ther       Date:  1986-05       Impact factor: 4.030

  7 in total
  7 in total

1.  Isolated limb perfusion for local gene delivery: efficient and targeted adenovirus-mediated gene transfer into soft tissue sarcomas.

Authors:  W K de Roos; J H de Wilt; M E van Der Kaaden; E R Manusama; M W de Vries; A Bout; T L ten Hagen; D Valerio; A M Eggermont
Journal:  Ann Surg       Date:  2000-12       Impact factor: 12.969

2.  20 years experience of TNF-based isolated limb perfusion for in-transit melanoma metastases: TNF dose matters.

Authors:  Jan P Deroose; Alexander M M Eggermont; Albertus N van Geel; Johannes H W de Wilt; Jacobus W A Burger; Cornelis Verhoef
Journal:  Ann Surg Oncol       Date:  2011-08-31       Impact factor: 5.344

3.  Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).

Authors:  A Kuin; M Aalders; M Lamfers; D J van Zuidam; M Essers; J H Beijnen; L A Smets
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

4.  Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.

Authors:  A L Vahrmeijer; J H van Dierendonck; H J Keizer; J H Beijnen; R A Tollenaar; M E Pijl; A Marinelli; P J Kuppen; J H van Bockel; G J Mulder; C J van de Velde
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

5.  Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies.

Authors:  J F Thompson; G A Siebert; Y G Anissimov; B M Smithers; A Doubrovsky; C D Anderson; M S Roberts
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

Review 6.  Molecular Aspects of the Isolated Limb Infusion Procedure.

Authors:  Jüri Teras; Michael J Carr; Jonathan S Zager; Hidde M Kroon
Journal:  Biomedicines       Date:  2021-02-07

7.  The effects of perfusion conditions on melphalan distribution in the isolated perfused rat hindlimb bearing a human melanoma xenograft.

Authors:  Z Y Wu; B M Smithers; P G Parsons; M S Roberts
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.